Lower respiratory tract microbiome in lung cancer after anti-tumor immunotherapy.
We aimed to clarify the compositional diversity in lower respiraotory tract microbiome after anti-tumor immunotherapy among lung cancer patients. Specific microbes mediated host interaction are also taken into account for uncovering the dominant microbial components in influencing the outcomes of immuno checkpoint blockade, which can be a potent diagnostic, therapeutic or evaluative target of anti-lung cancer immunotherapy in clinic.